Sukyeong Lee

Sukyeong Lee

Auto-generated profile, based on publicly available information

Sukyeong Lee

Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JLJungsoon Lee
Jungsoon Lee
JKJi-Hyun Kim
Ji-Hyun Kim
ABAmadeo B. Biter
Amadeo B. Biter
BSBernhard Sielaff
Bernhard Sielaff
SLSukyeong Lee
Sukyeong Lee
FTFrancis T.F. Tsai
Francis T.F. Tsai
Heat shock protein (Hsp) 104 is a ring-forming, protein-remodeling machine that harnesses the energy of ATP binding and hydrolysis to drive protein disaggregation. Although Hsp104 is an active ATPase, the recovery of functional protein requires the species-specific cooperation of the Hsp70 system. However, like Hsp104, Hsp70 is an active ATPase, which recognizes aggregated and aggregation-prone proteins, making it difficult to differentiate the mechanistic roles of Hsp104 and Hsp70 during protein disaggregation. Mapping the Hsp70-binding sites in yeast Hsp104 using peptide array technology and photo–cross-linking revealed a striking conservation of the primary Hsp70-binding motifs on the Hsp104 middle-domain across species, despite lack of sequence identity. Remarkably, inserting a Strep -Tactin binding motif at the spatially conserved Hsp70-binding site elicits the Hsp104 protein disaggregating activity that now depends on Strep- Tactin but no longer requires Hsp70/40. Consistent with a Strep -Tactin–dependent activation step, we found that full-length Hsp70 on its own could activate the Hsp104 hexamer by promoting intersubunit coordination, suggesting that Hsp70 is an activator of the Hsp104 motor.

1 August 2012 in Journal of Structural Biology
Verified
Journal Article
Closed access
ABAmadeo B. Biter
Amadeo B. Biter
JLJungsoon Lee
Jungsoon Lee
NSNuri Sung
Nuri Sung
FTFrancis T.F. Tsai
Francis T.F. Tsai
SLSukyeong Lee
Sukyeong Lee

1 February 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SLSukyeong Lee
Sukyeong Lee
SASteffen Augustin
Steffen Augustin
TTTakashi Tatsuta
Takashi Tatsuta
FGFlorian Gerdes
Florian Gerdes
TLThomas Langer
Thomas Langer
FTFrancis T.F. Tsai
Francis T.F. Tsai
FtsH-related AAA proteases are conserved membrane-anchored, ATP-dependent molecular machines, which mediate the processing and turnover of soluble and membrane-embedded proteins in eubacteria, mitochondria, and chloroplasts. Homo- and hetero-oligomeric proteolytic complexes exist, which are composed of homologous subunits harboring an ATPase domain of the AAA family and an H41 metallopeptidase domain. Mutations in subunits of mitochondrial m-AAA proteases have been associated with different neurodegenerative disorders in human, raising questions on the functional differences between homo- and hetero-oligomeric AAA proteases. Here, we have analyzed the hetero-oligomeric yeast m-AAA protease composed of homologous Yta10 and Yta12 subunits. We combined genetic and structural approaches to define the molecular determinants for oligomer assembly and to assess functional similarities between Yta10 and Yta12. We demonstrate that replacement of only two amino acid residues within the metallopeptidase domain of Yta12 allows its assembly into homo-oligomeric complexes. To provide a molecular explanation, we determined the 12 Å resolution structure of the intact yeast m-AAA protease with its transmembrane domains by electron cryomicroscopy (cryo-EM) and atomic structure fitting. The full-length m-AAA protease has a bipartite structure and is a hexamer in solution. We found that residues in Yta12, which facilitate homo-oligomerization when mutated, are located at the interface between neighboring protomers in the hexamer ring. Notably, the transmembrane and intermembrane space domains are separated from the main body, creating a passage on the matrix side, which is wide enough to accommodate unfolded but not folded polypeptides. These results suggest a mechanism regarding how proteins are recognized and degraded by m-AAA proteases.

29 February 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
NSNuri Sung
Nuri Sung
JLJungsoon Lee
Jungsoon Lee
JKJi-Hyun Kim
Ji-Hyun Kim
CCChangsoo Chang
Changsoo Chang
AJAndrzej Joachimiak
Andrzej Joachimiak
FTFrancis T.F. Tsai
Francis T.F. Tsai
Significance: Mitochondrial heat-shock protein of 90 kDa (Hsp90) (TRAP1) promotes cell survival and is essential for neoplastic growth. Exploiting human TRAP1 for drug development requires detailed structural and mechanistic understanding. Whereas TRAP1 adopts different conformations associated with distinct nucleotide states, how the TRAP1 dimer senses the bound nucleotide and signals this information to the neighboring subunit remains unknown. We show that unliganded TRAP1 forms a previously unobserved coiled-coil dimer and is found in an autoinhibited state. ATP binding in cis displaces the ATP lid that signals the nucleotide status to the trans subunit. Our findings suggest that human TRAP1 is a ligand-activated molecular chaperone, which couples ATP binding to local changes in structure facilitating dimer closure needed for protein folding.

1 January 2019 in Cell Reports
Verified
Journal Article
Open access
SLSukyeong Lee
Sukyeong Lee
SRSoung Hun Roh
Soung Hun Roh
JLJungsoon Lee
Jungsoon Lee
NSNuri Sung
Nuri Sung
JLJun Liu
Jun Liu
FTFrancis T.F. Tsai
Francis T.F. Tsai
Hsp104 is a ring-forming, ATP-driven molecular machine that recovers functional protein from both stress-denatured and amyloid-forming aggregates. Although Hsp104 shares a common architecture with Clp/Hsp100 protein unfoldases, different and seemingly conflicting 3D structures have been reported. Examining the structure of Hsp104 poses considerable challenges because Hsp104 readily hydrolyzes ATP, whereas ATP analogs can be slowly turned over and are often contaminated with other nucleotide species. Here, we present the single-particle electron cryo-microscopy (cryo-EM) structures of a catalytically inactive Hsp104 variant (Hsp104DWB) in the ATP-bound state determined between 7.7 Å and 9.3 Å resolution. Surprisingly, we observe that the Hsp104DWB hexamer adopts distinct ring conformations (closed, extended, and open) despite being in the same nucleotide state. The latter underscores the structural plasticity of Hsp104 in solution, with different conformations stabilized by nucleotide binding. Our findings suggest that, in addition to ATP hydrolysis-driven conformational changes, Hsp104 uses stochastic motions to translocate unfolded polypeptides.

17 February 2021 in Cancers
Verified
Journal Article
Open access
PDF file
LMLaure Maneix
Laure Maneix
MSMelanie A. Sweeney
Melanie A. Sweeney
SLSukyeong Lee
Sukyeong Lee
PIPolina Iakova
Polina Iakova
SMShannon Elizabeth Moree
Shannon Elizabeth Moree
ACAndre Catic
Andre Catic
Multiple myeloma and its precursor plasma cell dyscrasias affect 3% of the elderly population in the US. Proteasome inhibitors are an essential part of several standard drug combinations used to treat this incurable cancer. These drugs interfere with the main pathway of protein degradation and lead to the accumulation of damaged proteins inside cells. Despite promising initial responses, multiple myeloma cells eventually become drug resistant in most patients. The biology behind relapsed/refractory multiple myeloma is complex and poorly understood. Several studies provide evidence that in addition to the proteasome, mitochondrial proteases can also contribute to protein quality control outside of mitochondria. We therefore hypothesized that mitochondrial proteases might counterbalance protein degradation in cancer cells treated with proteasome inhibitors. Using clinical and experimental data, we found that overexpression of the mitochondrial matrix protease LonP1 (Lon Peptidase 1) reduces the efficacy of proteasome inhibitors. Some proteasome inhibitors partially crossinhibit LonP1. However, we show that the resistance effect of LonP1 also occurs when using drugs that do not block this protease, suggesting that LonP1 can compensate for loss of proteasome activity. These results indicate that targeting both the proteasome and mitochondrial proteases such as LonP1 could be beneficial for treatment of multiple myeloma.